STOCK TITAN

Zentalis Pharmaceuticals Inc - ZNTL STOCK NEWS

Welcome to our dedicated news page for Zentalis Pharmaceuticals (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zentalis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zentalis Pharmaceuticals's position in the market.

Rhea-AI Summary
Zentalis Pharmaceuticals presents promising preclinical data on azenosertib's synergistic anti-tumor activity with KRASG12C inhibitors at AACR 2024, showcasing potential for combination therapy in KRAS-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. granted non-qualified stock options to four new employees, totaling 105,950 shares, under the 2022 Inducement Plan. The options have an exercise price of $16.13 per share, a 10-year term, and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.54%
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. granted 125,000 non-qualified stock options to two new employees under the 2022 Inducement Plan. The options have an exercise price of $15.28 per share and a 10-year term, vesting over four years. This move aims to incentivize and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
none
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (ZNTL) will participate in upcoming investor conferences including TD Cowen 43rd Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Jefferies Biotech on the Bay Summit. The company aims to showcase its small molecule therapeutics for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
conferences
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. announces robust azenosertib clinical development plan with multiple clinical catalysts expected in 2024. The company's cash balance stood at $483 million as of December 31, 2023, providing funding into 2026. Key highlights include promising clinical data for azenosertib in ovarian cancer and uterine serous carcinoma, progress in ongoing Phase 1 trials, and strategic leadership team additions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. announced that Kimberly Blackwell, M.D., CEO, will participate in a webcast fireside chat at the Oppenheimer Healthcare Life Sciences Conference. The event is scheduled for February 14, 2024, at 12:40 p.m. ET. The webcast will be available on the company's website for live viewing and as an archived recording.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
conferences
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. announced the granting of non-qualified stock options and restricted stock units to six newly hired employees. The options have an exercise price of $11.69 per share and a 10-year term, vesting over four years. The restricted stock units will also vest over four years. The grants were made under the 2022 Inducement Plan as an inducement for entering into employment with Zentalis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. appoints Diana Hausman, M.D. as Chief Medical Officer and Kyle Rasbach, Ph.D., Pharm.D. as Chief Business Officer. Dr. Hausman brings extensive oncology development experience, having served as Chief Medical Officer in several biotech companies. Dr. Rasbach, with a background in healthcare equity research, joins from Eventide Asset Management. The company expresses gratitude to Dr. Carrie Brownstein, who is stepping down, for her contributions to advancing azenosertib in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary
Immunome, Inc. (IMNM) and Zentalis Pharmaceuticals, Inc. (ZNTL) have entered into an exclusive, worldwide license agreement for preclinical ROR1 ADC, with ZPC-21 on track for IND submission in 1Q 2025. Immunome will pay $35 million in cash and common stock to Zentalis, with potential milestone payments of up to $275 million and mid-to-high single-digit royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
none
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) granted non-qualified stock options to two newly hired employees under the 2022 Inducement Plan. The options have an exercise price of $15.99 per share, a 10-year term, and will vest over four years. Vesting is subject to the employee’s continued service to Zentalis on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Zentalis Pharmaceuticals Inc

Nasdaq:ZNTL

ZNTL Rankings

ZNTL Stock Data

951.58M
50.35M
4.22%
114.97%
21.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ZNTL

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer